Arthritis Drug Fails in Study of Covid-19 Patients
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Regeneron Pharmaceuticals Inc and Sanofi said on Thursday (2 June) their rheumatoid arthritis drug Kevzara failed to meet the main goals of a U.S. study testing it in the most critically ill COVID-19 patients.

Previous trial results had shown that the drug did not help patients with less severe COVID-19.

Kevzara belongs to a class of drugs called interleukin-6 inhibitors that are being tried to help regulate "cytokine storm."

Other drugs in the same class, including Roche Holding AG's Actemra, are also being studied as treatments for COVID-19.

A separate Sanofi-led trial of Kevzara outside of the United States in hospitalized patients with severe and critical COVID-19 using a different dosing regimen is ongoing, the companies said.

Source: https://health.economictimes.indiatimes.com/news/pharma/regeneron-sanofi-arthritis-drug-fails-covid-19-study/76761419
Dr. T●●●●z H●●●●●●i and 3 others like this1 share
Like
Comment
Share
Dr. S●●●●●m S●●●●y P●●●●●l
Dr. S●●●●●m S●●●●y P●●●●●l General Medicine
Interesting read!
Jul 4, 2020Like1